Ifinatamab deruxtecan by Daiichi Sankyo for Neuroendocrine Tumors: Likelihood of Approval

Af­ter re­al­iz­ing near­ly half a mil­lion dol­lars in prof­its, Stan­ley Ka­plan texted his friend in Russ­ian: “Let’s hope our gold­en goose will con­tin­ue lay­ing gold­en

As­traZeneca is mov­ing its block­buster can­cer drug Imfinzi in­to ear­li­er stages of small cell lung can­cer, a dis­ease that has not seen in­no­va­tion in stan­dard